Metformin Treatment for Multiple Sclerosis, Primary Progressive

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of California, Los Angeles, Los Angeles, CA
Multiple Sclerosis, Primary Progressive+4 More
Metformin 500 Mg Oral Tablet, up to 4 tablets a day - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

Eligible Conditions

  • Multiple Sclerosis, Primary Progressive
  • Secondary Progressive Multiple Sclerosis (SPMS)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Multiple Sclerosis, Primary Progressive

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: between month 0 and month 12

Month 12
a reduction in localized cortical thinning on brain MRI between baseline and conclusion (month 0 and month 12)
a reduction in thalamic atrophy on brain MRI between baseline and conclusion (month 0 and month 12)
decrease in number of phase rimmed lesions between baseline and conclusion (month 0 and month 12)
decrease in plasma neurofilament light chain levels between baseline and conclusion (month 0 and month 12)
improvement in CVLT-II score between baseline and conclusion (month 0 and month 12)
improvement in PACC score between baseline and conclusion (month 0 and month 12)
improvement in PASAT score between baseline and conclusion (month 0 and month 12)
improvement in SDMT-oral score between baseline and conclusion (month 0 and month 12)
number of patients with adverse events between baseline and conclusion (month 0 and month 12)
number of patients with laboratory abnormalities between baseline and conclusion (month 0 and month 12)
number of patients with new T2 lesions on MRI from baseline to conclusion (month 0 and month 12)
preservation of ganglion cell inner plexiform layer density between baseline and conclusion (month 0 and month 12)
preservation of retinal nerve fiber layer density between baseline and conclusion (month 0 and month 12)

Trial Safety

Safety Progress

1 of 3

Other trials for Multiple Sclerosis, Primary Progressive

Trial Design

2 Treatment Groups

Metformin Treatment
1 of 2
Placebo Treatment
1 of 2
Experimental Treatment
Non-Treatment Group

44 Total Participants · 2 Treatment Groups

Primary Treatment: Metformin Treatment · Has Placebo Group · Phase < 1

Metformin Treatment
Drug
Experimental Group · 1 Intervention: Metformin 500 Mg Oral Tablet, up to 4 tablets a day · Intervention Types: Drug
Placebo Treatment
Drug
PlaceboComparator Group · 1 Intervention: Placebo oral tablet identical to metformin, up to 4 tablets a day · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: between month 0 and month 12

Trial Background

Prof. Kevin Patel, Assistant Professor, Department of Neurology
Principal Investigator
University of California, Los Angeles
Closest Location: University of California, Los Angeles · Los Angeles, CA
Photo of Los Angeles  1Photo of Los Angeles  2Photo of Los Angeles  3
2004First Recorded Clinical Trial
1 TrialsResearching Multiple Sclerosis, Primary Progressive
216 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a diagnosis of primary progressive multiple sclerosis or secondary progressive multiple sclerosis as defined by the 2017 McDonald Criteria.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.